AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05132296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05410860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS 70 mg
Description: Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study NCT05410860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study NCT06678347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership for recovery
Description: The intervention will be delivered as a group-based programme (6 sessions) to the managers of the included employees. The programme includes educative and reflective parts as well as various strategies promoting both managers' own recovery and the recovery of employees.
Study NCT06689540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTS105
Description: MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg.
Study NCT05389670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta-burst stimulation (cTBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
Study NCT05389670 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Continuous Theta-burst stimulation (cTBS)
Description: Sham cTBS, inhibitory-like patterned form of TMS.
Study NCT05115669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wortie freeze plus
Description: treatment of common and plantar warts
Study NCT04716465 — intervention group
Intervention type: OTHER
Intervention: Dysautonomia
Description: Indicators of dysautonomia
Study NCT06693115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM with alerts
Description: CGM devices will be set to alert the care team when interstitial glucose levels hit 250 mg/dL and 150 mg/dL. Dexcom 7s automatically alert when glucose levels are 55 mg/dL or lower. Nurses will be instructed to check the glucose trends on the CGM device when alerted. They will be asked to check glucose levels with a FSBG according to the following instructions:~1. CGM alerts to interstitial glucose level of 250 mg/dL AND trend indicates rapidly decreasing glucose levels (indicated by double down arrow on Dexcom 7)~2. CGM alerts to interstitial glucose level of 150 mg/dL or less.
Study NCT06253650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice
Study NCT06253650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 4 cycles of: 5-fluorouracil 2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks, leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks, oxaliplatin 85 mg/m2 intravenous infusion on day 1 every 2 weeks, and docetaxel 50 mg/m2 intravenous infusion on day 1 every 2 weeks.
Study NCT06693791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim N01
Description: Romiplostim N01 was administered subcutaneously once weekly from +1 day to +28 days after UCBT at a recommended starting dose of 5µg/Kg (maximum single dose not to exceed 250µg) for a total of 4 administrations, with the option of continuation of dosing/switching/discontinuing after +28 days, depending on the patient's platelet profile.
Study NCT06693245 — intervention group
Intervention type: PROCEDURE
Intervention: VAS scores of the puncture
Description: All patients were evaluated by our team with CEAP grading and ultrasound measurements to record the diameter of the saphenous vein before surgery。We performed endovenous microwave ablation of the great saphenous vein along with foam sclerotherapy and point stripping treatment. We documented the operating room temperature, puncture site, VAS scores during puncture and catheter placement, the amount of injected tumescent fluid, radiofrequency generator used, and data at the conclusion of the surgery. A descriptive analysis of intraoperative pain scores was conducted to evaluate the level of pain experienced during the surgery. A nonparametric test was utilized to analyze the relationship between preoperative and intraoperative factors and the level of pain experienced during the surgery.
Study NCT06691906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide decanoate
Description: Oral tablet
Study NCT06715436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mediterranean Diet
Description: The MedDiet will be planned according to the Mediterranean diet pyramid
Study NCT06715436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Modified Atkins diet with a maximum of 20 g of carbohydrates per day.
Study NCT06475807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fermented food
Description: Step 1: patients will consume high-fermented food
Study NCT06475807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber supplementation
Description: Step 2: High fiber supplementation
Study NCT06715436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control group
Description: The control group will be asked to continue their dietary and lifestyle habits
Study NCT06230874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME Protocol
Description: The HOME Protocol is a newly developed nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Five components of the HOME Protocol include Reflect (1 minute of self-reflection and self-talk), Reset (2 minutes for breathing with stillness/silence and body check), Reach (3 minutes for stretching and progressive muscular relaxation), Renew (2 minutes for breathing with meditation/gratitude), and Re-engage (1 minute for self-reflection and self-talk).
Study NCT06230874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Journaling Protocol
Description: The control journaling protocol is a nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness self-talk and journaling strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Three components of the control journaling protocol include Reflect (1 minute of self-reflection and self-talk), Write (journaling), and Re-engage (1 minute for self-reflection and self-talk).
Study NCT05982600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Single Assessor Teledermatological triage (TDT)
Description: The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
Study NCT05982600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2 people Teledermatological triage (TDT)
Description: The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
Study NCT05202288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ervebo
Description: Administration of r-VSV-ZEBOV vaccine
Study NCT05202288 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ervebo
Description: Administration of r-VSV-ZEBOV vaccine
Study NCT05202288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inmazeb
Description: Administration of Inmazeb
Study NCT05521022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-02
Description: AT-02 via IV infusion
Study NCT05521022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AT-02 (Placebo)
Description: Normal saline solution via IV infusion
Study NCT06745336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-001
Description: CS-001 Topical Treatment
Study NCT06745336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Solution
Description: Placebo Topical Solution
Study NCT05982600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3 people Teledermatological triage (TDT)
Description: The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
Study NCT05982600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 5 people Teledermatological triage (TDT)
Description: The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
Study NCT06047262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapansutrile
Description: Patients receive investigational product.
Study NCT06047262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo.
Study NCT06290544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care plus additional examinations
Description: The patient will undergo good clinical practice examinations according to guidelines plus The patient will undergo to the evaluation of endothelial dysfunction with ENDOPAT 2000 and whole blood sampling for future omics studies
Study NCT05403307 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Study NCT05403307 — intervention group
Intervention type: BIOLOGICAL
Intervention: CoronaVac COVID-19 vaccine
Description: CoronaVac COVID-19 vaccine
Study NCT00012987 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality Improvement
Study NCT05397457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level light therapy
Description: Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks.
Study NCT05082883 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Risk Assessment Cognitive Screening
Description: Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks
Study NCT04675255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frequently sampled glucose tolerance testing
Description: Frequently sampled glucose tolerance testing
Study NCT04913519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-105795
Description: TDM-105795 topical solution
Study NCT04913519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for TDM-105795 topical solution
Study NCT05158010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HELIX's follow-up
Description: * Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary~* Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples.
Study NCT04675255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal subcutaneous adipose tissue biopsy
Description: abdominal subcutaneous adipose tissue biopsy
Study NCT04675255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan to assess intrahepatic triglyceride content
Description: MRI scan to assess intrahepatic triglyceride content
Study NCT04238234 — intervention group
Intervention type: DEVICE
Intervention: IVC Ultrasonography
Description: Ultrasound measurements will be performed using a curved transducer set to abdominal mode (1-5 MHz; Acuson x300; Siemens Healthcare, Seoul, Korea). IVC variation will be assessed using ultrasound in the long-axis (sagittal) view. IVC diameter will be measured 1 cm distal to its junction with hepatic vein either by 2-D or M modes via a subcostal approach according to the methodology described by the American Society of Echocardiography . A two-dimensional image of the IVC as it enters the right atrium will be first obtained.
Study NCT04238234 — intervention group
Intervention type: DEVICE
Intervention: Plethysmographic variability index (PVI) and perfusion index readings (PI)
Description: The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA).~PVI (%) is a measure of the dynamic change in PI that occurs during one or more complete respiratory cycles, calculated as:~PVI= \[(PImax-PImin)/PImax\] x100
Study NCT06747585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALE.P02
Description: ALE.P02, will be administered by IV infusion according to the assigned arms.
Study NCT06746480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Description: Intratumoral injection only. The dosing date is Days 1 through 3.
Study NCT06746987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: After the appropriate sample group for the research is created, study and control groups will be determined. Firstly, randomization of the study and control groups in the research will be done by an independent researcher on the randomizer.org website. Secondly, the Pitsburg Sleep Quality Scale and PERMA test will be applied to the study and control groups as a pre- test. Thirdly, theta healing meditation will be applied to the study group for 4 weeks, 2 days a week, 15- 30 minutes a day. After the 4 week meditation practice is completed with the study group, a final test will be given to the study and control groupsthe Pitsburg Sleep Quality Scale and PERMA test will be applied as the final test.
Study NCT06746272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: Ultrasound guided Serratus anterior block will be performed according to the analgetic standard in our department using an ultrasound guided transducer to inject 2mg/kg of 0.5% ropivacaine with an adjuvant. A sterile plaster will be placed on the puncture site after performing the block. Patients will receive i.v. analgesia according to the analgesic standard of care in our department.
Study NCT06746909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidomain cognitive training and physical training
Description: The cognitive training programme will be based on 8 cycles composed by 18 sessions of exercises and activities aimed at stimulating multiple cognitive functions. Each cycle will last 3 weeks, after which the same kind of cognitive stimulation sessions will be restarted, with exercises and activities of increased complexity. Each cycle will be structured in sessions aimed at stimulating specific cognitive domains and in sessions focused on multimodal activities (music-therapy, cineforum, etc.).~The physical training will include aerobic exercise on an ergometer cycle, whose duration will be increased gradually from 10 to 20 minutes followed by exercises targeted to improve muscle strength, physical function, neuromuscular control and flexibility.
Study NCT06746350 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermotherapy
Description: Radio frequency-induced heat treatment using the ThermoMed device at 50-degree centigrade for 30 seconds.
Study NCT06746350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Description: Radio frequency-induced heat treatment using the ThermoMed device at 50-degree centigrade for 30 seconds.
Study NCT06747975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Ondansetron
Description: patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline
Study NCT06747975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + saline
Description: patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline
Study NCT06747975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine + saline
Description: patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline
Study NCT06747325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fei Re Qing Granules
Description: Fei Re Qing Granules (Ingredients: Scutellaria baicalensis \[Huang Qin\], Trichosanthes kirilowii \[Gua Lou\], Forsythia suspensa \[Lian Qiao\], Fritillaria thunbergii \[Zhe Bei Mu\], etc.)
Study NCT06747325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine standard treatments
Description: Routine standard treatments
Study NCT06747325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine standard treatments
Description: Routine standard treatments
Study NCT05159141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Description: The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
Study NCT06747325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granules
Description: The placebo granules are prepared using 5% of the active drug, ensuring consistency in appearance, weight, color, and odor with the Fei Re Qing Granules
Study NCT05100472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2. Bicalutamide will be continued through radiation and then discontinued on the day of the last fraction. Leuprolide can be given at different doses, but must be given for a total planned duration of 6 months.
Study NCT05100472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: After approximately 3 months (+/- 1 month) of neoadjuvant ADT, patients will undergo general anesthesia for outpatient transperineal high dose rate (HDR) interstitial prostate brachytherapy implant.
Study NCT05100472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated pelvic External beam radiation
Description: Patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
Study NCT06326866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Study NCT06747416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN057
Description: KN057 will be administered subcutaneously once a week.
Study NCT05471726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective audit-and-feedback
Description: The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge.
Study NCT06278064 — intervention group
Intervention type: OTHER
Intervention: Gastric Cancer
Description: Patients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer
Study NCT05166902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (comfilcon A lens)
Description: 1 month
Study NCT05166902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lehfilcon A lens)
Description: 1 month
Study NCT06278064 — intervention group
Intervention type: OTHER
Intervention: Esophagus Cancer
Description: Patients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer
Study NCT04854213 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Radiation treatment